Molbio Diagnostics Limited
RHP · filed 07 Aug 2026
Molbio Diagnostics Limited is a diagnostic company that reported revenue of Rs 54.3 crore and profit of Rs 8.1 crore in the latest fiscal year, with revenue growing at a CAGR of 30.06%. The company's financial trajectory is supported by a debt-to-equity ratio of 0.32 and a return on equity of 8.39%. The draft prospectus highlights material risks regarding high customer concentration, as government and international aid agencies accounted for over 84% of revenue, and a significant reliance on tuberculosis test kits, which constituted over 70% of sales.
What stands out
Auditor qualification. Emphasis of Matter paragraph regarding fraud and provision of ₹ 199.00 Million against earnest money deposits (EMD) of Prognosys Medical Systems Private Limited. Qualifications/Modifications under section Other Legal and Regulatory Requirements for years ended March 31, 2026, March 31, 2025 and Marc
Risk factor. Revenue is highly concentrated with government and international aid agencies, which accounted for 84.56%, 87.83% and 91.60% of revenue from finished goods sales in Fiscals 2026, 2025 and 2024, respectively.
Risk factor. Revenue is highly concentrated with the top 10 customers, which accounted for 83.26%, 83.62% and 78.54% of revenue from finished goods sales in Fiscals 2026, 2025 and 2024, respectively.
Risk factor. Revenue from the sale of diagnostic test kits for tuberculosis (TB) accounted for 70.20%, 69.11% and 62.40% of revenue from finished goods sales in Fiscals 2026, 2025 and 2024, respectively.
Low leverage. Debt-to-equity of 0.32x.
Strong revenue growth. Restated revenue CAGR of 30.1%.
How the offer is structured
- Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec and connected office space for our Company, Subsidiaries and Associate₹106 Cr
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit₹72.3 Cr
- General corporate purposes
Restated financials
Revenue
₹54.3 Cr
Latest fiscal year
Profit after tax
₹8.1 Cr
Revenue CAGR
30.1%
Return on equity
8.4%
Debt / equity
0.32
PAT CAGR
61.6%
| Fiscal year | Revenue | EBITDA | PAT | Net worth |
|---|---|---|---|---|
| 2024 | ₹32.1 Cr | ₹3.1 Cr | ₹83.2 Cr | |
| 2025 | ₹43.2 Cr | ₹5.2 Cr | ₹88.4 Cr | |
| 2026 | ₹54.3 Cr | ₹8.1 Cr | ₹96.5 Cr |
Auditor qualification. Emphasis of Matter paragraph regarding fraud and provision of ₹ 199.00 Million against earnest money deposits (EMD) of Prognosys Medical Systems Private Limited. Qualifications/Modifications under section Other Legal and Regulatory Requirements for years ended March 31, 2026, March 31, 2025 and March 31, 2024. Disclaimer of opinion relating to Section 143(3)(i) of the Act on the audit of Internal Financial Controls for the year ended March 31, 2024.
Promoters, litigation & related parties
Promoter (pre)
46.6%
Risks the company discloses
Revenue is highly concentrated with government and international aid agencies, which accounted for 84.56%, 87.83% and 91.60% of revenue from finished goods sales in Fiscals 2026, 2025 and 2024, respectively.(Customer Concentration)
Revenue is highly concentrated with the top 10 customers, which accounted for 83.26%, 83.62% and 78.54% of revenue from finished goods sales in Fiscals 2026, 2025 and 2024, respectively.(Customer Concentration)
Revenue from the sale of diagnostic test kits for tuberculosis (TB) accounted for 70.20%, 69.11% and 62.40% of revenue from finished goods sales in Fiscals 2026, 2025 and 2024, respectively.(Product Concentration)
Arrangements with international aid agencies typically involve framework agreements or understandings that do not include firm commitments regarding the quantity of devices or test kits to be procured.(Contractual Terms)
The procurement process often involves tendering, which poses a risk if products do not meet specific criteria or pricing requirements set by government tenders or international aid agencies.(Procurement Process)
Government agencies may cap the selling prices of products below economic levels or impose procurement ceilings that limit the volume of purchases.(Regulatory Risk)
The loss of any of the top 10 customers or a decline in demand from them could have an adverse impact on the business, financial condition, results of operations and cash flows.(Customer Concentration)
The volume and timing of sales to the top 10 customers may vary due to variation in demand for services of such customers.(Customer Concentration)
How this document reads, dimension by dimension
Each bar is a fixed formula applied to the figures shown above, scored 0–100. This is a reading of what the company disclosed — not a recommendation to apply or avoid, not a price target, and not a prediction of listing performance. Dimensions that could not be extracted are excluded rather than assumed, so coverage varies between documents.